AI Tool Comparison
Comparing as AI Medical Imaging & DiagnosticsPaige vs PathAI
Compare features, pricing, pros & cons, and user ratings to decide which AI tool is best for your needs.
Paige
VS
PathAI
Verdict by Category
AI content generation failed. Refresh the page to try again.
Detailed Comparison
Feature
Paige
PathAI
Pricing
EnterprisePaige operates exclusively on enterprise contracts with hospital pathology departments, cancer centers, and biopharma companies. There is no published pricing or self-serve option.
Clinical deployments are priced based on institution size, scanner ecosystem, patient volume, and AI modules deployed (FullFocus, Paige Prostate, Paige Breast, etc.). Biopharma partnerships are structured as research service agreements for biomarker discovery, companion diagnostic development, and drug trial tissue analysis.
Contact Paige through paige.ai to arrange an enterprise discovery call and platform demonstration.
EnterprisePathAI operates exclusively on enterprise contracts with hospitals, pathology labs, and biopharma companies — there is no published pricing or self-serve access. Following its acquisition by Roche in May 2026, PathAI's commercial and contract terms are managed through Roche's diagnostics division.
Clinical lab engagements use AISight for digital pathology workflow integration and AI algorithm deployment. Biopharma partnerships are structured as research service contracts for clinical trial tissue analysis, biomarker discovery, and companion diagnostic development.
Contact PathAI or Roche Diagnostics to explore enterprise and research partnership options.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Summary
Computational pathology AI from MSK — the first FDA-cleared platform for AI-assisted cancer diagnosis
AI-powered digital pathology platform for oncology diagnostics and biopharma R&D — now part of Roche
Paige Pros & Cons
Pros
- First FDA clearance for AI in primary pathology diagnosis — a historic regulatory milestone
- First CE mark for AI pathology in Europe — validated for clinical use across EU
- Founded on MSK's 25M+ pathology slides — the richest cancer pathology training set in the world
- AIRI infrastructure with 10+ petaFLOPS — enterprise-grade AI compute at clinical scale
- FullFocus viewer is scanner-neutral with FDA clearances for Leica, Hamamatsu, and Philips
- The most credentialed AI pathology company in terms of regulatory approvals
- Backed by Goldman Sachs, Breyer Capital, and Healthcare Venture Partners
Cons
- Enterprise and institutional access only — not available to small or independent pathology labs
- No published pricing — all contracts negotiated through enterprise procurement
- Requires digital pathology infrastructure — scanners, storage, and LIS integration
- Pathologist review and sign-off still required for all AI-generated results
- Focused on pathology and oncology — not a general medical imaging platform
PathAI Pros & Cons
Pros
- Acquired by Roche (May 2026) — now backed by the world's largest diagnostics company
- 32.5M+ expert annotations — one of the world's largest pathology AI training datasets
- 20+ AI algorithms covering oncology, liver disease, and tumor microenvironment analysis
- AISight is scanner-neutral — works with Leica, Hamamatsu, Philips scanners with FDA clearance
- CLIA-certified lab services for biopharma clinical trial support
- Partnerships with BMS, Merck, Moffitt Cancer Center, and University Hospital Zurich
- First AI pathology company recognized as a leader in CB Insights Digital Pathology market map
Cons
- Acquired by Roche in May 2026 — future product roadmap and independent operations may change
- Enterprise and biopharma-focused — not accessible to independent pathologists or small labs
- No self-serve pricing or trial — all engagements are through enterprise procurement
- Requires digital pathology infrastructure (scanners, storage, LIS integration)
- Integration complexity for labs not yet on digital pathology workflows